BofA raised the firm’s price target on Crispr Therapeutics (CRSP) to $93 from $78 and keeps a Buy rating on the shares. The firm, which continues to see Casgevy growth in the near-term, updated its model to include revenue builds for several in vivo gene editing programs, CTX112 in autoimmune conditions, and SRSD107, adding that it believes the company’s pipeline potential is “underappreciated.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics AG Files $600M Share Offering
- Crispr Therapeutics price target raised to $75 from $65 at Wells Fargo
- Crispr Therapeutics AG: Promising Advancements in Gene Editing and Strategic Market Entry Justify Buy Rating
- Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical Data
- Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy Rating